Antibody therapeutics are not only effective for patients who experience insufficient effects from conventional drugs, but can also reduce the risk of side effects via bonding to specific targets. Antibody therapeutics for cancer and the field of intractable disease are being continuously developed and used for treatment at clinical sites all around the world.

In recent years, many kinds of antibody therapeutics have been increasing in number due to innovations in antibody engineering technology. The strengths and weaknesses of antibodies have a significant effect on the results of the ensuing pharmaceutical development.

By establishing a technological platform that can effectively produce specifically targeted and functional antibodies, and by expanding it to the development of new drugs as well as other products and services, our company contributes to the creation of better pharmaceuticals and diagnostic drugs.

Antibody

Antibody therapeutics are not only effective for patients who experience insufficient effects from conventional drugs, but can also reduce the risk of side effects via bonding to specific targets. Antibody therapeutics for cancer and the field of intractable disease are being continuously developed and used for treatment at clinical sites all around the world.

In recent years, many kinds of antibody therapeutics have been increasing in number due to innovations in antibody engineering technology. The strengths and weaknesses of antibodies have a significant effect on the results of the ensuing pharmaceutical development.

By establishing a technological platform that can effectively produce specifically targeted and functional antibodies, and by expanding it to the development of new drugs as well as other products and services, our company contributes to the creation of better pharmaceuticals and diagnostic drugs.

Antibody

The history of vaccines dates back to the end of the 18th century with Edward Jenner’s discovery of the smallpox vaccine, and continues to this day, as various vaccines have contributed to medical care by preventing infectious disease.

In recent years, the complicated workings of the body’s immune system have become clearer. Due to many illnesses occurring as a result of breakdown of the immune system, vaccines are extensively used in medical care.

Our company has developed a particulate polymer that is able to greatly increase activation of the immune system. This polymer has the ability to successfully increase humoral and cellular immunity, and we have found that it has the potential to perform and be safely used to excellent effect. We look to propose new treatment concepts by constructing a highly functional adjuvant based on this polymer, developing safe and highly effective vaccines, and expanding its use to other products and services.

Adjuvant

CELLBANKER is a series of cell cryopreservation media and has been our leading product since it became commercially available in 1991. The medium achieves over 80% cell viability after thawing for most cell lines, and occupies over 70% of the share in experimental reagents in Japan. At present, we are developing novel applications of the CELLBANKER series to meet the needs of current research trends. In particular, the discovery of induced pluripotent stem cells (iPS cells) and related research efforts in recent years are leading the field of regenerative medicine as a novel industry to realize practical applications.

Regenerative medicine has opened new avenues for curing patients with difficult-to-treat diseases and diseases that are resistant to conventional therapies.

We are transforming the CELLBANKER series from being experimental in nature to being applicable in regenerative medicine in terms of quality and functionality, as well as addressing current issues with cryopreservation in basic research and clinical settings.

Cellbanker

Contract Manufacturing of Biologics

We are collaborating with ZENOAQ, our group company, to provide services for contract manufacturing of human biopharmaceuticals at ZENOAQ biological manufacturing plant permitted by the Pharmaceuticals and Medical Devices Agency (PMDA, Japan). The facilities also comply with cGMP and PIC/S GMP guidelines. We are able to carry out contract manufacturing on a scale that meets the needs of the client, ranging from seed cultures to mass quantity cultures of up to two thousand liters. Having the manufacturing plants to handle production of various products, we also work flexibly according to our clients' requests and goals, from conducting a wide variety of tests, including raw material tests, in-process tests, and product tests, to cell bank production and GMP manufacturing.

We provide support for these contract services from inquiries to contract conclusion and provision of deliverables.

Biomedicine